Carisma Therapeutics (CARM)
搜索文档
Carisma Therapeutics (CARM) - 2021 Q3 - Quarterly Report
2021-11-08 00:00
Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SESN The Nasdaq Stock Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...
Carisma Therapeutics (CARM) - 2021 Q2 - Quarterly Report
2021-08-09 00:00
Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SESN The Nasdaq Stock Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t ...
Carisma Therapeutics (CARM) - 2021 Q1 - Earnings Call Transcript
2021-05-10 23:36
Sesen Bio, Inc. (SESN) Q1 2021 Results Earnings Conference Call May 10, 2021 8:00 AM ET Company Participants Erin Clark - Vice President of Investor Relations Thomas Cannell - President and Chief Executive Officer Chad Myskiw - Strategic Planning, CMC Monica Forbes - Chief Financial Officer Conference Call Participants John Newman - Canaccord Roger Song - Jefferies Operator Good day and thank you for standing by. Welcome to the Sesen Bio Quarter One 2021 Business Update Call. At this time, all participants ...
Carisma Therapeutics (CARM) - 2021 Q1 - Earnings Call Presentation
2021-05-10 21:04
seser b i o 1Q 2021 Business Update May 10, 2021 NASDAQ: SESN FORWARD- LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical development of our protein therapies, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forw ...
Carisma Therapeutics (CARM) - 2021 Q1 - Quarterly Report
2021-05-10 00:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36296 Sesen Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2025616 (State or ot ...
Carisma Therapeutics (CARM) - 2020 Q4 - Annual Report
2021-03-15 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SESN The Nasdaq Global Market FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commiss ...
Carisma Therapeutics (CARM) - 2020 Q3 - Quarterly Report
2020-11-10 05:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36296 Sesen Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2025616 (State o ...
Carisma Therapeutics (CARM) - 2020 Q3 - Earnings Call Transcript
2020-11-10 00:12
Sesen Bio, Inc. (SESN) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Erin Clark - Vice President of Investor Relations Thomas Cannell - President and Chief Executive Officer Chad Myskiw - Strategic Planning, CMC Monica Forbes - Chief Financial Officer Conference Call Participants John Newman - Canaccord Genuity Operator Ladies and gentlemen, thank you for standing by and welcome to the Sesen Bio Third Quarter 2020 Business Update Conference Call. At this time, all partici ...
Carisma Therapeutics (CARM) - 2020 Q3 - Earnings Call Presentation
2020-11-09 22:04
seser i b O 3Q 2020 Business Update November 9, 2020 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical development of our protein therapies, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forwardlooking ...
Carisma Therapeutics (CARM) - 2020 Q2 - Quarterly Report
2020-08-11 04:19
Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SESN The Nasdaq Stock Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t ...